

CARESCIENCE INC
Form 10-Q
November 12, 2002

[QuickLinks](#) -- Click here to rapidly navigate through this document

FORM 10-Q
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2002

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from _____ to _____.
COMMISSION FILE NUMBER: 0-30859

CARESCIENCE, INC.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

PENNSYLVANIA
(STATE OR OTHER JURISDICTION
OF INCORPORATION OR ORGANIZATION)

23-2703715
(I.R.S. EMPLOYER
IDENTIFICATION NO.)

3600 MARKET STREET
PHILADELPHIA, PA 19104
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(ZIP CODE)

(215) 387-9401
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

(FORMER NAME, FORMER ADDRESS AND FORMER FISCAL YEAR, IF CHANGED SINCE LAST REPORT)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

The number of shares of the registrant's Common Stock outstanding, as of November 7, 2002 was 13,300,391.

CARESCIENCE, INC.

FORM 10-Q

SEPTEMBER 30, 2002

INDEX

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Consolidated Balance Sheets September 30, 2002 and December 31, 2001 (unaudited) 2

Consolidated Statements of Operations Three and Nine Months Ended September 30, 2002 and September 30, 2001 (unaudited) 3

Consolidated Statements of Cash Flows Nine Months Ended September 30, 2002 and September 30, 2001 (unaudited) 4

Notes to Consolidated Financial Statements 5

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 10

Item 3. Quantitative and Qualitative Disclosures About Market Risk 15

Item 4. Controls and Procedures 15

PART II. OTHER INFORMATION

Item 1. Legal Proceedings 16

Item 2. Changes in Securities and Use of Proceeds 16

Item 6. Exhibits and Reports on Form 8-K 17

Signatures 18

1

PART I. FINANCIAL INFORMATION

ITEM 1. Financial Statements

CARESCIENCE, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS

	September 30, 2002	December 31, 2001
	(unaudited)	
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 13,318,991	\$ 8,860,436
Short-term investments	4,983,080	12,000,950
Interest receivable	14,695	83,821
Accounts receivable, net of allowance for doubtful accounts of \$77,054 and \$68,354, respectively	1,364,598	1,207,094
Prepaid expenses and other	715,284	479,696

Edgar Filing: CARESCIENCE INC - Form 10-Q

	September 30, 2002	December 31, 2001
Total current assets	20,396,648	22,631,997
Property and equipment:		
Computer equipment	5,348,752	4,707,706
Office equipment	546,857	471,754
Leasehold improvements	169,956	169,956
Furniture and fixtures	516,059	508,598
	6,581,624	5,858,014
Less Accumulated depreciation and amortization	(4,298,856)	(3,345,267)
Net property and equipment	2,282,768	2,512,747
Other assets	151,493	155,639
Goodwill, net	1,245,687	1,245,687
Total assets	\$ 24,076,596	\$ 26,546,070
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Current portion of capital lease obligations and notes payable	\$ 349,324	\$ 207,747
Accounts payable	472,478	529,809
Accrued expenses	1,243,286	1,196,176
Deferred revenues	3,130,250	3,535,484
Total current liabilities	5,195,338	5,469,216
Capital lease obligations	133,012	200,069
Notes payable	231,725	
Commitments and contingencies		
Shareholders' equity:		
Preferred stock, no par value, 20,000,000 shares authorized, no shares issued or outstanding		
Common stock, no par value, 100,000,000 shares authorized, 14,740,391 shares issued and 13,300,391 shares outstanding, and; 14,720,016 shares issued and 13,280,016 shares outstanding, respectively	60,282,656	60,256,012
Additional paid-in capital	4,838,843	5,008,718
Deferred compensation	(1,243,369)	(2,202,250)
Accumulated other comprehensive income	32,123	57,852
Accumulated deficit	(44,198,399)	(40,923,547)
Subscriptions receivable	(295,333)	(420,000)
Treasury stock, at cost, 1,440,000 shares	(900,000)	(900,000)
Total shareholders' equity	18,516,521	20,876,785
Total liabilities and shareholders' equity	\$ 24,076,596	\$ 26,546,070

Edgar Filing: CARESCIENCE INC - Form 10-Q

September 30, 2002	December 31, 2001
_____	_____
_____	_____

The accompanying notes are an integral part of these statements.

2

**CARESCIENCE, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS**

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2002	2001	2002	2001
	(unaudited)			
Revenues	\$ 3,715,892	\$ 3,557,760	\$ 10,528,521	\$ 9,125,916
Cost of revenues	1,771,351	1,826,459	5,159,826	5,098,627
Gross profit	1,944,541	1,731,301	5,368,695	4,027,289
Operating expenses:				
Research and development	656,186	850,339	2,010,566	3,197,432
Selling, general and administrative	2,083,339	2,563,107	6,893,036	8,885,085
Total operating expenses	2,739,525	3,413,446	8,903,602	12,082,517
Operating loss	(794,984)	(1,682,145)	(3,534,907)	(8,055,228)
Interest income	(116,720)	(247,675)	(299,572)	(889,652)
Interest expense	18,238	23,497	39,517	66,215
Net loss	\$ (696,502)	\$ (1,457,967)	\$ (3,274,852)	\$ (7,231,791)
Net loss per common share:				
Basic and diluted	\$ (0.05)	\$ (0.11)	\$ (0.25)	\$ (0.55)
Weighted average shares outstanding:				
Basic and diluted	13,300,391	13,277,384	13,295,988	13,108,855

The accompanying notes are an integral part of these statements.

3

**CARESCIENCE, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS**

For the Nine Months Ended September 30,	
2002	2001
_____	_____
_____	_____

Edgar Filing: CARESCIENCE INC - Form 10-Q

For the Nine Months Ended
September 30,

(unaudited)

Cash flows from operating activities:		
Net loss	\$ (3,274,852)	\$ (7,231,791)
Adjustments to reconcile net loss to net cash used in operating activities		
Depreciation and amortization	978,225	1,034,710
Loss on disposal		158,000
Provision for bad debts	9,000	14,475
Stock-based compensation	789,006	947,396
Changes in assets and liabilities		
(Increase) decrease in		
Interest receivable	69,126	119,559
Accounts receivable	(166,504)	(270,076)
Prepaid expenses and other	(235,588)	(495,571)
Other assets	4,146	
Increase (decrease) in		
Accounts payable and accrued expenses	114,446	(1,057,447)
Deferred revenues	(405,234)	805,068
Net cash used in operating activities	(2,118,229)	(5,975,677)
Cash flows from investing activities:		
Purchases of short-term investments	(13,884,634)	(8,000,000)
Proceeds from the redemption of short-term investments	20,876,775	5,000,115
Cash paid for acquisition		(882,367)
Purchases of property and equipment	(724,661)	(302,155)
Net cash provided by (used in) investing activities	6,267,480	(4,184,407)
Cash flows from financing activities:		
Proceeds from the exercise of common stock options	26,644	4,883
Payments on capital lease obligations and note payable	(271,090)	(343,805)
Proceeds from notes payable	553,750	237,751
Net cash provided by (used in) financing activities	309,304	(101,171)
Net increase (decrease) in cash and cash equivalents	4,458,555	(10,261,255)
Cash and cash equivalents, beginning of period	8,860,436	26,702,096
Cash and cash equivalents, end of period	\$ 13,318,991	\$ 16,440,841

The accompanying notes are an integral part of these statements.

(1) Summary of Significant Accounting Policies

Organization and Basis of Presentation

CareScience, Inc. (the "Company") provides Internet-based tools designed to improve the quality and efficiency of health care. The Company uses its proprietary clinical algorithms and data collection and storage technologies to perform complex clinical analyses. The Company's customers use its services to identify clinical inefficiencies and medical errors and monitor the results of implemented solutions. Additionally, the Company facilitates the real-time exchange of clinical information over the Internet among local health care constituents.

The consolidated balance sheet as of September 30, 2002, the consolidated statements of operations for the three and nine months ended September 30, 2002 and 2001 and the consolidated statements of cash flows for the nine months ended September 30, 2002 and 2001 have been prepared by the Company without audit. In the opinion of management, all adjustments, consisting of normal and recurring adjustments, necessary to present fairly the financial position, results of operations and cash flows as of September 30, 2002 and for all periods presented have been made.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The results of operations for the three and nine months ended September 30, 2002 are not necessarily indicative of the operating results for the full year.

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of CareScience, Inc. and its subsidiary. All significant intercompany transactions and balances have been eliminated.

Recent Accounting Pronouncements

On January 1, 2002, the Company adopted SFAS No. 142, "Goodwill and Other Intangible Assets." This statement modifies existing generally accepted accounting principles related to the amortization and impairment of goodwill and other intangible assets. Goodwill, including goodwill associated with equity method investments, will no longer be amortized. In addition, goodwill, other than goodwill associated with equity method investments, must be assessed at least annually for impairment using a fair-value based approach. Impairment losses that arise due to the initial application of this statement are to be reported as a cumulative effect of change in accounting principle. The Company has completed an analysis of the impact of implementing the provisions of this statement as of January 1, 2002 and has determined that there is no impairment loss. With the adoption of this new standard, as of January 1, 2002 the Company discontinued the amortization of the

goodwill balance. The following proforma disclosure is included pursuant to the disclosure requirements of SFAS 142:

	For the Three Months Ended September 30,		For the Nine Months Ended September 30,	
	2002	2001	2002	2001
Reported net loss	\$ (696,502)	\$ (1,457,967)	\$ (3,274,852)	\$ (7,231,791)
Add back Goodwill amortization		66,149		129,069
Adjusted net loss	\$ (696,502)	\$ (1,391,818)	\$ (3,274,852)	\$ (7,102,722)
Basic and diluted net loss per Common share:				
Reported net loss	\$ (0.05)	\$ (0.11)	\$ (0.25)	\$ (0.55)
Goodwill amortization		0.01		0.01
Adjusted net income	\$ (0.05)	\$ (0.10)	\$ (0.25)	\$ (0.54)

Edgar Filing: CARESCIENCE INC - Form 10-Q

In August 2001, the FASB issued SFAS No. 144, "Accounting for the Impairment or Disposal of Long-lived Assets", which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. SFAS No. 144 supersedes SFAS No. 121, "Accounting for the Impairment of Long-lived Assets and for Long-lived Assets to be Disposed Of", and the accounting and reporting provisions of APB Opinion No. 30, "Reporting the Results of Operations for a disposal of a segment of a business". SFAS No. 144 is effective for fiscal years beginning after December 15, 2001, with earlier application encouraged. The impact of adopting this accounting standard did not have a material effect on the Company's financial position or results of operations.

In January 2002, the Financial Accounting Standards Board's Emerging Issues Task Force (EITF) reached a consensus on EITF Issue 01-14, "Income Statement Characterization of Reimbursements Received for "Out-of-Pocket" Expenses Incurred." This consensus requires that reimbursements received for out-of-pocket expenses incurred are characterized as revenue in the statement of operations. The Company adopted EITF 01-14 effective January 1, 2002 and has made the appropriate reclassifications as required by EITF 01-14. The effect of adopting EITF 01-14 was to increase revenues and expenses by \$23,000 and \$69,000 for the three and nine months ended September 30, 2002, respectively and \$49,000 and \$125,000 for three and nine months ended September 30, 2001, respectively.

Cash and Cash Equivalents and Short-term Investments

The Company invests excess cash in highly liquid investment-grade marketable securities including corporate commercial paper and U.S. government agency bonds. For financial reporting purposes, the Company considers all highly liquid investment instruments purchased with an original maturity of three months or less to be cash equivalents. All investment instruments with maturities greater than three months are available for use in current operations and accordingly are classified as current assets. All investments are considered available-for-sale and accordingly, unrealized gains and losses are included in a separate component of shareholders' equity.

6

As of September 30, 2002 cash and cash equivalents and short-term investments at cost and fair market value consisted of the following:

	September 30, 2002		
	Original Cost	Unrealized Gains	Fair Market Value
Cash and cash equivalents	\$ 13,318,991	\$	\$ 13,318,991
Short-term investments	4,950,957	32,123	4,983,080
	<u>\$ 18,269,948</u>	<u>\$ 32,123</u>	<u>\$ 18,302,071</u>

At September 30, 2002 short-term investments consisted of five debt instruments maturing between October 31, 2002 and February 14, 2003.

Supplemental Cash Flow Information

The Company paid interest of \$39,517 and \$66,215 for the nine months ended September 30, 2002 and 2001, respectively.

The Company financed \$23,585 and \$0 of property and equipment purchases with capital leases for the nine months ended September 30, 2002 and 2001, respectively.

Revenue Recognition

The Company generates revenue from subscriptions to its internet based proprietary technology applications and hosting of customer data, as well as development agreements and consulting services.

The Company's agreements for its internet based tools, which typically cover an initial period of one-to-five years and are fixed priced, provide to customers, among other things, a software license, project management services, data management services, data storage and computer server maintenance and software support and maintenance. Revenues under these contracts are recognized ratably over the contract period. Any additional consulting fees, outside of the initial contract, are recognized as the service is delivered.

Edgar Filing: CARESCIENCE INC - Form 10-Q

The Company's development agreements, with periods ranging from three-to-five years, provide for customer funding for the development of new solutions and services. In accordance with Staff Accounting Bulletin (SAB) No. 101, "Revenue Recognition in Financial Statements", the Company is treating revenue on these agreements as a single element contract and is recognizing total revenue on a cost-to-cost basis over the entire agreement period.

The Company's various consulting services are delivered either as a single program or as a project whose completion normally occurs over a several month period. Consulting revenues from program services are recorded as the program is completed. Consulting revenues from projects are recorded on a percentage of completion basis over the term of the project.

Major Customers

The Company's operations are conducted in one business segment and sales are primarily made to health care payors and providers. One customer accounted for 10% and two customers accounted for 22% of total revenues for the three and nine months ended September 30, 2002. One different customer accounted for 10% of total accounts receivable as of September 30, 2002. Two customers accounted for 22% and one customer accounted for 13% of total revenues for the three months and nine months ended September 30, 2001, respectively. As of December 31, 2001, a different customer represented 12% of accounts receivable.

7

Comprehensive Income

Accumulated other comprehensive income consists of unrealized gains and losses on available for sale securities as follows:

Balance, December 31, 2001	\$ 57,852
Current-period change	(25,729)
	<hr/>
Balance, September 30, 2002	\$ 32,123
	<hr/>

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual amounts could differ from those estimates.

Reclassifications

Certain amounts have been reclassified in the prior years consolidated financial statements to conform to the 2002 presentation.

(2) Net Loss per Share

Net loss per share is calculated utilizing the principles of SFAS No. 128, "Earnings per Share" ("EPS"). Basic EPS excludes potentially dilutive securities and is computed by dividing net income available to common shareholders by the weighted-average number of common shares outstanding for the period. Diluted EPS is computed assuming the conversion or exercise of all dilutive securities such as options and warrants.

Under SFAS No. 128, the Company's granting of certain stock options and warrants resulted in potential dilution of basic EPS. The number of incremental shares from the assumed exercise of stock options and warrants is calculated applying the treasury stock method. Stock options and warrants and convertible into common shares were excluded from the calculations as they were anti-dilutive due to the net loss. Stock options to purchase 2,047,873 shares of common stock at exercise prices ranging from \$0.25 to \$12.00 were outstanding as of September 30, 2002, but were excluded from the computation of diluted net loss per share since the inclusion would be anti-dilutive due to the net loss.

(3) Commitments and Contingencies

Litigation

Edgar Filing: CARESCIENCE INC - Form 10-Q

The Company and certain of its officers are defendants in a purported class action litigation pending in the United States District Court for the Eastern District of Pennsylvania. The complaints purport to bring claims on behalf of all persons who allegedly purchased Company common stock between June 29, 2000 and November 1, 2000, for alleged violations of the federal securities laws, including Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 by issuing a materially false and misleading Prospectus and Registration Statement with respect to the initial public offering of Company common stock. Specifically, the complaints allege, among other things, that the Company's Prospectus and Registration Statement misrepresented and omitted to disclose material facts concerning the Company's competitors, two of the Company's prospective products and the Company's contract with the California HealthCare Foundation. The actions seek compensatory and other damages, and costs and expenses associated with litigation. Although the Company cannot predict the ultimate outcome of

8

the case or estimate the range of any potential loss that may be incurred in the litigation, management believes the lawsuits are frivolous and without merit, strenuously denies all allegations of wrongdoing asserted by plaintiffs, and believes it has meritorious defenses to plaintiffs' claims. The Company intends to vigorously defend the lawsuits. Management believes that the resolution of this litigation will not have a material effect on our consolidated financial position or results of operations.

(4) Income Taxes

The Company has incurred operating losses and generated a significant accumulated deficit through September 30, 2002, therefore, no tax provisions have been recorded. As of September 30, 2002 the Company had federal net operating loss carryforwards of approximately \$34 million which expire from 2010 through 2021. As of September 30, 2002 and September 30, 2001, a valuation allowance was recorded for 100% of the Company's deferred tax asset as realization of the tax benefit was not considered more likely than not under the provisions of SFAS No. 109.

The Tax Reform Act of 1986 contains certain provisions that limit the utilization of net operating losses and tax credit carryforwards if there has been a cumulative ownership change greater than 50% within a three-year period. Such limitation could result in the expiration of the net operating losses before such losses are fully utilized.

9

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

This report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. We use words such as anticipates, believes, expects, future, intends, and similar expressions to identify forward-looking statements. For these statements we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. There are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including:

the difficulty in evaluating our business because we operate in a new industry and our operating history is limited;

we have a history of losses and expect our losses to continue;

the proprietary technology we own or license may be subjected to infringement claims or disagreements with the licensor which could be costly to resolve;

we depend on an exclusive license with the University of Pennsylvania and an exclusive license with the California HealthCare Foundation for some of our technology, and the loss of these licenses would impair our ability to develop our business;

Edgar Filing: CARESCIENCE INC - Form 10-Q

we could be liable for information retrieved from our Web sites and incur significant costs from resulting claims;

we may experience system failures which could interrupt our service and damage our customer relationships;

the health care industry may not accept our solutions or buy our services which would adversely affect our financial results;

because our revenues are dependent on a limited number of services, the failure of any one of these services would significantly decrease our revenues;

termination of one or more of our significant contracts would cause a significant decline in our revenue;

failure to manage our growth would adversely affect our operations;

we face intense competition and may be unable to compete successfully which would adversely effect our financial results;

the loss of any of our key personnel could adversely affect our operations;

our failure to develop strategic relationships could adversely affect our ability to develop new services;

our failure to use new technologies effectively or to adapt emerging industry standards would adversely affect our ability to compete;

our failure to adapt our technology to our customers' needs or to handle high levels of customer activity would adversely affect our ability to increase revenue;

failure by our service providers could interrupt our business and damage our customer relationships;

we may need to obtain additional capital and failure to do so may limit our growth;

health information is subject to potential government regulation and legal uncertainties and changes may require us to alter our business;

10

changes in the health care industry could adversely affect our operations;

our business will suffer if commercial users do not accept Internet solutions;

our industry is evolving and we may not adapt successfully.

Overview

CareScience, Inc. is a provider of online care management services. Our mission is to transform the quality and efficiency of care delivery by providing innovative clinical information technology to the health care industry. We market our services to hospitals, health systems and

Edgar Filing: CARESCIENCE INC - Form 10-Q

pharmaceutical and biotechnology manufacturers, and support more than 150 customers in 40 states.

We work with health care providers to manage clinical processes surrounding the point of care so that fundamental reductions in errors and operating cost can be achieved. Our products collect, share, store and analyze clinical data generated by widely used health information systems. Our services allow customers to apply this data to the management of care, including quality monitoring, practice improvement, credentialing, profiling, error tracking, case management and clinical guidelines. We also provide consulting services to healthcare providers that support strategic planning and clinical operations.

For the pharmaceutical and biotechnology industry, we provide services that shorten the drug development cycle and improve development yield. Our offerings consulting services, customized research and strategic development support. These services are aimed at the specialized drug development needs of pharmaceutical industry clinicians, product managers, market strategists, health economists and outcomes researchers.

We have pioneered and commercialized numerous clinical information technologies. We have developed one of the nation's first online quality measurement and management tools, one of the first clinically based outcome risk assessment algorithms, one of the first health care application service providers, and, most recently, the first peer-to-peer clinical data sharing technology. We have developed these tools in collaboration with leading public organizations, including the Wharton School of Business at the University of Pennsylvania, the National Library of Medicine, Los Alamos National Laboratory and The California HealthCare Foundation.

CareScience was incorporated in 1992 with the purpose of commercializing intellectual property that was developed at the University of Pennsylvania School of Medicine and The Wharton School of Business. In 1993, we exclusively licensed the intellectual property underlying our core technology in a 30-year agreement with the University of Pennsylvania. In 1996, we launched our first Internet-based commercial product based on this proprietary technology under our Care Management System product line. In 1999, we initiated our Care Data Exchange, as well as our Lifecycle Decision System, which is aimed at the pharmaceutical and biotechnology industries. On March 7, 2000, we changed our name from Care Management Science Corporation to CareScience, Inc.

We generate revenues from subscriptions to our Internet-based proprietary technology applications and hosting of customer data, as well as from consulting services and development agreements. We sell our services individually or as an integrated suite of solutions and services. We price our subscription services on a per-encounter basis, such as the number of a hospital's patient admissions or outpatient visits.

Our agreements for our internet based tools, which typically cover an initial period of one-to-five years and are fixed priced, provide to customers, among other things, a software license, project management services, data management services, data storage and computer server maintenance and software support and maintenance. Revenues under these contracts are recognized ratably over the contract period.

11

Our development agreements, with periods ranging from one-to-five years, provide for customer funding for the development of new solutions and services. In accordance with Staff Accounting Bulletin (SAB) No. 101, "Revenue Recognition in Financial Statements", the Company is treating revenue on these agreements as a single element contract and is recognizing total revenue on a cost-to-cost basis over the entire agreement period.

Our various consulting services are delivered either as a single program or as a project whose completion normally occurs over a several month period. Consulting revenues from program services are recorded as the program is completed. Consulting revenues from projects are recorded on a percentage of completion basis over the term of the project.

Our contracts generally provide for payment in advance of services rendered. Therefore, we record these payments as deferred revenues and recognize these payments when earned in accordance with our revenue recognition policy. Our deferred revenue balances were \$3.1 million and \$3.5 million at September 30, 2002 and December 31, 2001, respectively.

We have incurred substantial research and development costs since inception and have also invested in our corporate infrastructure to support our long-term growth strategy. We expect that our operating expenses will continue at historic or greater levels as we further our product development and sales and marketing efforts. Accordingly, we expect to continue to incur quarterly net losses for the foreseeable future.

Since inception, we have incurred cumulative net losses for federal and state tax purposes and have not recognized any tax provision or benefit. As of December 31, 2001, we had net operating loss carryforwards of approximately \$34.0 million for federal income tax purposes. The net operating loss carryforwards, if not utilized, expire from 2010 through 2021. Federal tax laws impose significant restrictions on the utilization of net operating loss carryforwards in the event of an ownership change as defined in Section 382 of the Internal Revenue Code.

Results of Operations

Three Months Ended September 30, 2002 and September 30, 2001

Revenues

Total revenues increased 4% to \$3.7 million for the three months ended September 30, 2002 from \$3.6 million for the three months ended September 30, 2001. The increase was primarily related to revenues generated from additional customer and development contracts.

Unrecognized revenues related to customer and development contracts (backlog) as of September 30, 2002 totaled \$26.4 million.

Cost of Revenues

Cost of revenues include customer and service-related costs including personnel and facility costs, depreciation and maintenance. Cost of revenues for the three months ended September 30, 2002 was \$1.8 million a decrease of \$55,000 or 3% compared to \$1.8 million for the three months ended September 30, 2001. We have been able to service an increasing revenue base while keeping cost of revenues relatively constant as a result of cost control initiatives.

Gross Profit

Our gross profit margin increased from 49% for the three months ended September 30, 2001, to 52% for the three months ended September 30, 2002. The increase in gross profit margin is primarily due to increased revenues spread over a partially fixed cost base, as well as the results of our cost control initiatives.

12

Research and Development

Research and development costs include technology and product development costs. Research and development costs for the three months ended September 30, 2002 were \$656,000, a decrease of \$194,000 or approximately 23%, compared to \$850,000 for the three months ended September 30, 2001. This decrease is primarily due to lowering costs as certain development projects near completion.

As a percentage of revenue, research and development costs were 18% for the three months ended September 30, 2002 as compared to 24% for the three months ended September 30, 2001. As we continue to invest in research and development, we expect these costs will increase as a percentage of revenue in the future.

Selling, General and Administrative Expenses

Selling, general and administrative expenses include costs associated with our sales, marketing, finance, human resource and administrative functions. Selling, general and administrative expenses for the three months ended September 30, 2002 were \$2.1 million, a decrease of \$480,000, or 19% compared to \$2.6 million for the three months ended September 30, 2001. The decrease was primarily related to a reduction in marketing and other administrative expenditures in 2002 as part of the company's efforts of reducing costs.

As a percentage of revenues, selling, general, and administrative expenses were 56% for the three months ended September 30, 2002 as compared to 72% for the three months ended September 30, 2001. We expect the percentage of selling, general and administrative costs to increase as a percentage of revenues in the future as we invest in new sales and marketing initiatives in order to promote growth in revenues.

Stock-Based Compensation

We granted certain stock options to our officers and employees with exercise prices deemed to be below the fair market value of the underlying stock. The remaining cumulative difference between the fair value of the underlying stock at the date the options were granted and the exercise price of the granted options was \$1.2 million at September 30, 2002. We expect to amortize this amount over the remaining one to four year vesting periods of the granted options. Accordingly, our results from operations will include stock-based compensation expense at least through 2006. We recognized \$262,000 and \$316,000 of this expense during the three months ended September 30, 2002 and 2001, respectively.

Interest Income and Expense

Edgar Filing: CARESCIENCE INC - Form 10-Q

Net interest income for the three months ended September 30, 2002 was \$98,000, a decrease of \$126,000, compared to \$224,000 for the three months ended September 30, 2001. The decrease is primarily due to lower investable cash balances and a decrease in investment interest rates.

Nine Months Ended September 30, 2002 and September 30, 2001

Revenues

Total revenues increased 15% to \$10.5 million for the nine months ended September 30, 2002 from \$9.1 million for the nine months ended September 30, 2001. The increase was primarily related to revenues generated from additional customer and development contracts.

Unrecognized revenues related to customer and development contracts (backlog) as of September 30, 2002 totaled \$26.4 million.

13

Cost of Revenues

Cost of revenues includes customer and service-related costs including personnel and facility costs, depreciation and maintenance. Cost of revenues for the nine months ended September 30, 2002 was \$5.2 million an increase of \$61,000 or 1%, compared to \$5.1 million for the nine months ended September 30, 2001. We have been able to service an increasing revenue base while keeping cost of revenues relatively constant as a result of a partially fixed cost base as well as cost control initiatives.

Gross Profit

Our gross profit margin increased from 44% for the nine months ended September 30, 2001, to 51% for the nine months ended September 30, 2002. The increase in gross profit margin is primarily due to increased revenues spread over a partially fixed cost base, as well as the results of our cost control initiatives.

Research and Development

Research and development costs include technology and product development costs. Research and development costs for the nine months ended September 30, 2002 were \$2.0 million, a decrease of \$1.2 million or approximately 37%, compared to \$3.2 million for the nine months ended September 30, 2001. This decrease is primarily due to lowering costs as certain development projects were completed.

As a percentage of revenue, research and development costs were 19% for the nine months ended September 30, 2002 as compared to 35% for the nine months ended September 30, 2001. As we continue to invest in research and development, we expect these costs will increase as a percentage of revenue in the future.

Selling, General and Administrative Expenses

Selling, general and administrative expenses include costs associated with our sales, marketing, finance, human resource and administrative functions. Selling, general and administrative expenses for the nine months ended September 30, 2002 were \$6.9 million, a decrease of \$2.0 million, or 22% compared to \$8.9 million for the nine months ended September 30, 2001. The decrease was primarily related to a planned reduction in marketing and other administrative expenditures in 2002 as part of the company's efforts of reducing costs.

As a percentage of revenues, selling, general, and administrative expenses were 65% for the nine months ended September 30, 2002 as compared to 97% for the nine months ended September 30, 2001. We expect the percentage of selling, general and administrative costs to increase as a percentage of revenues in the future as we invest in new sales and marketing initiatives in order to promote growth in revenues.

Stock-Based Compensation

We granted certain stock options to our officers and employees with exercise prices deemed to be below the fair market value of the underlying stock. The remaining cumulative difference between the fair value of the underlying stock at the date the options were granted and the exercise price of the granted options was \$1.2 million at September 30, 2002. We expect to amortize this amount over the remaining one to four year vesting periods of the granted options. Accordingly, our results from operations will include stock-based compensation expense at least through 2006. We recognized \$789,000 and \$947,000 of this expense during the nine months ended September 30, 2002 and 2001, respectively.

Interest Income and Expense

Net interest income for the nine months ended September 30, 2002 was \$260,000, a decrease of \$563,000, compared to \$823,000 for the nine months ended September 30, 2001. The decrease is primarily due to lower investable cash balances and a decrease in investment interest rates.

Liquidity and Capital Resources September 30, 2002

Since inception, we have financed our operations and funded our capital expenditures through the public offering and private sale of equity securities, supplemented by private debt and equipment leases. We believe that current capital resources will be sufficient to fund anticipated capital expenditures and working capital requirements for at least the next 12 months. As of September 30, 2002, we had \$18.3 million in cash and cash equivalents and short-term investments and working capital of \$15.2 million.

Net cash used in operating activities was \$2.1 million for the nine months ended September 30, 2002 and \$6.0 million for the nine months ended September 30, 2001. For those periods, net cash used in operating activities was primarily to fund losses from operations offset by changes in current assets and liabilities.

Net cash provided by investing activities was \$6.3 million for the nine months ended September 30, 2002 and consisted primarily of the net proceeds from the redemption of short-term investments offset with purchases of property and equipment. Net cash used in investing activities was \$4.2 million for the nine months ended September 30, 2001 and consisted primarily of the net purchases of short-term investments offset with funding of an acquisition and purchases of property and equipment.

Net cash provided by financing activities was \$309,000 for the nine months ended September 30, 2002 and consisted of proceeds from notes payable and the exercise of common stock options net of payments on capital lease obligations and notes payable. Net cash used in financing activities consisted of \$101,000 for nine months ended September 30, 2001, and consisted of payments on capital lease obligations net of proceeds from a note payable and the exercise of common stock options.

As we execute our strategy, we expect significant increases in our operating expenses to fund development of current and new divisions and product lines. Presently, we anticipate that our existing capital resources will meet our operating and investing needs for at least the next 12 months. After that time, additional funding may not be available on acceptable terms or at all. If we require additional capital resources to grow our business, execute our operating plans or acquire complementary businesses at any time in the future, we may seek to sell additional equity or debt securities or secure additional lines of credit, which may result in ownership dilution to our shareholders.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our cash equivalents, short-term investments and capital lease obligations are at fixed interest rates and therefore the fair market value of these instruments is affected by changes in market interest rates. As of September 30, 2002 all of our short-term investments mature within 5 months and we had the ability to immediately liquidate our investments. Therefore, we believe that we are exposed to immaterial levels of market risk.

ITEM 4. CONTROLS AND PROCEDURES

a.

Within the 90 days prior to the date of filing of this report, we carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chairman and Chief Executive Officer along with Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-14. Based upon that evaluation, the Company's Chairman and Chief Executive Officer

along with the Chief Financial Officer concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to the Company (including its consolidated subsidiary) required to be included in our periodic SEC

filings.

b.

There have been no significant changes in our internal controls or in other factors that could significantly affect internal controls subsequent to the date we carried out this evaluation.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We and certain of our officers are defendants in a purported shareholder class action lawsuit litigation pending in the United States District Court for the Eastern District of Pennsylvania described below for alleged violations of federal securities laws. Although we cannot predict the ultimate outcome of the case or estimate the range of any potential loss that may be incurred in the litigation, we believe the lawsuits are frivolous and without merit, strenuously deny all allegations of wrongdoing asserted by plaintiffs, and believe we have meritorious defenses to plaintiffs' claims. We intend to vigorously defend the lawsuits. We believe that the resolution of this litigation will not have a material effect on our business, financial condition or results of operations.

The class action litigation is the result of several complaints filed with the court beginning on October 17, 2001. These actions were consolidated on November 16, 2001. The court approved the selection of the lead plaintiff in the litigation on March 12, 2002. We filed a motion to dismiss the consolidated complaint on August 7, 2002. These complaints purport to bring claims on behalf of all persons who allegedly purchased our common stock between June 29, 2000 and November 1, 2000, for alleged violations of the federal securities laws, including Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 by issuing a materially false and misleading Prospectus and Registration Statement with respect to the initial public offering of our common stock. Specifically, the complaints allege, among other things, that our Prospectus and Registration Statement misrepresented and omitted to disclose material facts concerning our competitors, two of our prospective products and our contract with the California HealthCare Foundation. The actions seek compensatory and other damages, and costs and expenses associated with litigation.

We are not involved in any other legal proceedings that either individually or taken as a whole would have a material adverse effect on our business, financial condition or results of operations.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

USE OF PROCEEDS

On June 28, 2000 the Securities and Exchange Commission declared effective our Registration Statement on Form S-1 (File number 333-32376), relating to the initial public offering of our Common Stock, no par value per share. The net offering proceeds to us after total expenses were \$43.4 million. As of September 30, 2002, we have used approximately \$26.1 million of the net proceeds from our initial public offering of which approximately \$15.8 million was used for working capital and other general corporate purposes, including expansion of our sales and marketing efforts as well as development of our solutions and services, approximately \$6.5 million was used for dividends on and the redemption of preferred stock, approximately \$3.4 million was used for the purchase of property plant and equipment, including technology and equipment expenditures required to support our product development infrastructure and \$1.1 million was used for the acquisition of Strategic Outcomes Services, Inc.,

None of the net proceeds from the offering were used to pay, directly or indirectly, directors, officers, persons owning ten percent or more of the Company's equity securities, or affiliates of the Company.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a)

Exhibits

See Exhibit Index

(b)
Reports on Form 8-K

July 18, 2002 to report Changes in Registrant's Certifying Accountant under Item 4 of Form 8-K.

17

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CARESCIENCE, INC.

Date: November 7, 2002

By: /s/ DAVID J. BRAILER

David J. Brailer
Chairman and Chief Executive Officer

Date: November 7, 2002

By: /s/ STEVEN BELL

Steven Bell, *Chief Financial Officer and Treasurer*
18

Sarbanes-Oxley Section 302(a) Certification

I, David J. Brailer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CareScience, Inc.;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
 - a) designed such disclosure controls and procedures to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
 - b) evaluated the effectiveness of the registrant's disclosure controls and procedures as of a date within 90 days prior to the filing date of this quarterly report (the "Evaluation Date"); and
 - c)

Edgar Filing: CARESCIENCE INC - Form 10-Q

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

ITEM 4. CONTROLS AND PROCEDURES

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

Sarbanes-Oxley Section 302(a) Certification

Sarbanes-Oxley Section 302(a) Certification

EXHIBIT INDEX